Inhibrx Inc (INBX)
34.05
-0.04
(-0.12%)
USD |
NASDAQ |
Apr 26, 16:00
34.05
0.00 (0.00%)
After-Hours: 17:43
Inhibrx Cash and Short Term Investments (Quarterly): 277.92M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 277.92M |
| September 30, 2023 | 337.33M |
| June 30, 2023 | 192.49M |
| March 31, 2023 | 234.25M |
| December 31, 2022 | 273.86M |
| September 30, 2022 | 146.07M |
| June 30, 2022 | 176.38M |
| March 31, 2022 | 143.47M |
| December 31, 2021 | 131.30M |
| Date | Value |
|---|---|
| September 30, 2021 | 112.70M |
| June 30, 2021 | 125.73M |
| March 31, 2021 | 107.99M |
| December 31, 2020 | 128.66M |
| September 30, 2020 | 127.67M |
| June 30, 2020 | 5.632M |
| December 31, 2019 | 11.54M |
| June 30, 2019 | 27.62M |
| March 31, 2019 | 6.244M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
5.632M
Minimum
Jun 2020
337.33M
Maximum
Sep 2023
150.63M
Average
131.30M
Median
Dec 2021
Cash and Short Term Investments (Quarterly) Benchmarks
| Johnson & Johnson | 22.93B |
| Gilead Sciences Inc | 7.264B |
| Outlook Therapeutics Inc | 10.36M |
| Axonics Inc | 344.96M |
| NovaBay Pharmaceuticals Inc | 3.13M |